Fairscale Capital LLC Sells 2,369 Shares of Pfizer Inc. (NYSE:PFE)

Fairscale Capital LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 39.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,710 shares of the biopharmaceutical company’s stock after selling 2,369 shares during the period. Fairscale Capital LLC’s holdings in Pfizer were worth $98,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Sowell Financial Services LLC boosted its stake in shares of Pfizer by 2.6% in the fourth quarter. Sowell Financial Services LLC now owns 180,359 shares of the biopharmaceutical company’s stock worth $4,785,000 after acquiring an additional 4,581 shares during the period. AlphaQuest LLC boosted its stake in Pfizer by 26.1% in the 4th quarter. AlphaQuest LLC now owns 24,083 shares of the biopharmaceutical company’s stock worth $639,000 after purchasing an additional 4,987 shares during the period. Roberts Glore & Co. Inc. IL grew its holdings in Pfizer by 4.2% during the 4th quarter. Roberts Glore & Co. Inc. IL now owns 40,993 shares of the biopharmaceutical company’s stock valued at $1,088,000 after buying an additional 1,649 shares in the last quarter. Coordinated Financial Services Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $207,000. Finally, Axis Wealth Partners LLC purchased a new position in shares of Pfizer in the fourth quarter worth $290,000. 68.36% of the stock is currently owned by institutional investors.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating and set a $33.00 target price on shares of Pfizer in a research note on Monday, February 10th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Truist Financial decreased their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Up 1.8 %

Shares of NYSE PFE opened at $26.71 on Monday. The business has a fifty day moving average price of $26.30 and a 200 day moving average price of $27.23. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market capitalization of $151.35 billion, a P/E ratio of 18.94, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% compared to the same quarter last year. During the same period last year, the business earned $0.10 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 7th. Stockholders of record on Friday, January 24th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.44%. Pfizer’s dividend payout ratio is presently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.